Related Experiment Videos

Severe persistent injection site reactions after subcutaneous 2'-O-methyl phosphorothioate oligonucleotide therapy

Joana Domingos¹, Valeria Ricotti¹, Anna E Martinez²

¹Dubowitz Neuromuscular Centre, UCL Great Ormond Street Institute of Child Health and Great Ormond Street Hospital, 30 Guilford Street, London WC1N 1EH, UK.

Neuromuscular Disorders : NMD

|January 7, 2018

Abstract

No abstract available in PubMed .

Keywords:

Antisense oligonucleotide Duchenne muscular dystrophy Exon skipping Morphea-like skin lesion Subcutaneous injections

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Factors Impacting Laxative Use in Children and Adolescents With Epidermolysis Bullosa: Single Centre Retrospective Study.

Journal of paediatrics and child health·2026

Eliciting health state utilities for open wounds in dystrophic epidermolysis bullosa.

Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation·2026

Mesenchymal stromal cell infusions of umbilical cord-derived mesenchymal stromal cells in children with Recessive Dystrophic Epidermolysis Bullosa (MissionEB): a qualitative sub study of a randomised, double-blind, placebo controlled, crossover, phase 3 trial.

Orphanet journal of rare diseases·2026

Long-Term Efficacy and Safety of Oleogel-S10 (Birch Triterpenes) for Pediatric Patients With Epidermolysis Bullosa.

Pediatric dermatology·2026

Assessment of hand contractures in epidermolysis bullosa (ACE-EB): Describing the development of a novel hand assessment for children.

Hand therapy·2026

Mesenchymal stromal cell infusions of umbilical cord-derived mesenchymal stromal cells in children with recessive dystrophic epidermolysis bullosa (MissionEB): a randomised, double-blind, placebo controlled, crossover, phase 3 trial with an internal phase 1 dose de-escalation phase.

EClinicalMedicine·2025

See all related articles